期刊
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
卷 9, 期 10, 页码 1289-1297出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17512433.2016.1232164
关键词
Orlistat; phentermine/topiramate; Qsymia; naltrexone/bupropion; Contrave; Iorcaserin; Belviq; Iiraglutide; Saxenda
Introduction: Obesity is a major health concern for several countries. The United States (U.S.) has arguably led the world in the percentage of overweight and/or obese per capita for several decades. As a result, numerous FDA-approved pharmacotherapeutic options are available for the long-term treatment of obesity. Although most of these medications have been on the U.S. market for a few years and have demonstrated efficacy for long-term weight loss in clinical trials, the impact of these medications on obesity in the U.S. has yet to be realized. Areas covered: We will review and evaluate why pharmacotherapy for obesity has not produced a meaningful reduction in the number of overweight and obese adults in the U.S. Expert commentary: Several obstacles, such as adverse drug effects, poor insurance coverage, not treating obesity as a chronic disease, and availability of other weight loss alternatives, has resulted in poor performance of pharmacotherapy for obesity in the U.S. market.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据